ProCE Banner Activity

Novel, Next-Generation HIV-1 Maturation Inhibitor GSK3640254 Demonstrates Dose-Dependent Antiviral Response in Treatment-Naive Patients With HIV Infection

Slideset Download
Conference Coverage
Phase IIa study demonstrates that novel maturation inhibitor exhibits dose-response antiviral activity, in vivo concentrations above clinical efficacy targets, and good tolerability.

Released: March 10, 2021

Expiration: March 09, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare